chronic kidney disease

News

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

News

Unicycive eyes June FDA verdict for hyperphosphataemia drug

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis, which hopes to improve on 'onerous' phos

News

Novo sheds kidney drug licensed for $1.3bn a year ago

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

News

Lexicon's type 1 diabetes drug voted down by FDA adcomm

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.

News

Boehringer says R&D pipeline is the best in its long history

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that

News

Study warns of chronic kidney disease timebomb

Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, a

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Unicycive eyes June FDA verdict for hyperphosphataemia drug

Novo sheds kidney drug licensed for $1.3bn a year ago

Lexicon's type 1 diabetes drug voted down by FDA adcomm

Boehringer says R&D pipeline is the best in its long history

Study warns of chronic kidney disease timebomb

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

chronic kidney disease

Editor's Picks